Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
about
Cancer therapies utilizing the camptothecins: a review of the in vivo literaturePopulation pharmacokinetic/pharmacodynamic modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors.Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss something in CPT analogue molecular targets for treating human disease such as cancer?
P2860
Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Population pharmacokinetic and ...... urtotecan in phase II studies.
@en
Population pharmacokinetic and ...... urtotecan in phase II studies.
@nl
type
label
Population pharmacokinetic and ...... urtotecan in phase II studies.
@en
Population pharmacokinetic and ...... urtotecan in phase II studies.
@nl
prefLabel
Population pharmacokinetic and ...... urtotecan in phase II studies.
@en
Population pharmacokinetic and ...... urtotecan in phase II studies.
@nl
P2093
P356
P1476
Population pharmacokinetic and ...... urtotecan in phase II studies.
@en
P2093
Cortes-Funes H
Dombernowsky P
Hanauske AR
Heinrich B
P2888
P356
10.1023/A:1014454821885
P577
2002-02-01T00:00:00Z
P6179
1013802648